Commentary|Articles|June 17, 2026

ADA 2026: Lipid Management and Cardiovascular Prevention Updates for People With Diabetes

Author(s)Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP

Fact checked by: Gillian McGovern, Editor

Identifying high-risk patients, optimizing lipid-lowering therapy, and helping patients achieve evidence-based targets remain critical to improving cardiovascular outcomes.

Cardiovascular disease remains the leading cause of morbidity and mortality among people with diabetes. Although advances in glucose-lowering therapies have transformed diabetes management, residual cardiovascular risk remains substantial. At the 86th American Diabetes Association (ADA) Scientific Sessions, several important presentations focused on lipid management and cardiovascular prevention, highlighting both persistent treatment gaps and emerging therapies that may help further reduce cardiovascular risk.